^
CANCER:

Adrenal Cortex Carcinoma

Phase N/A
National Cancer Institute (NCI)
Recruiting
Last update posted :
07/01/2022
Initiation :
01/17/2012
TP53
|
TP53 mutation
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/30/2022
Initiation :
08/24/2020
Primary completion :
04/02/2024
Completion :
04/08/2024
NF1
|
paclitaxel • Tasigna (nilotinib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/30/2022
Initiation :
01/13/2017
Primary completion :
10/31/2023
Completion :
10/31/2023
CD4
|
PD-L1 overexpression • PD-L1 amplification
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
GlaxoSmithKline
Recruiting
Last update posted :
06/14/2022
Initiation :
10/06/2020
Primary completion :
09/28/2029
Completion :
03/15/2030
TMB • BRCA1 • BRCA2 • BRCA
|
BRCA2 mutation • BRCA1 mutation
|
Zejula (niraparib) • Jemperli (dostarlimab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
05/25/2022
Initiation :
05/08/2017
Primary completion :
06/30/2021
Completion :
07/01/2022
MET • RET • AXL
|
MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression
|
Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
PharmaMar
Recruiting
Last update posted :
05/24/2022
Initiation :
09/06/2017
Primary completion :
02/13/2023
Completion :
02/13/2023
BRCA
|
BRCA mutation
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • ecubectedin (PM14)
Phase 1
St. Jude Children's Research Hospital
Not yet recruiting
Last update posted :
04/26/2022
Initiation :
05/01/2022
Primary completion :
03/01/2026
Completion :
03/01/2027
CD276
|
CD276 expression
|
cyclophosphamide • fludarabine IV • mesna • B7-H3 CAR-T • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
Infinity Pharmaceuticals, Inc.
Active, not recruiting
Last update posted :
04/04/2022
Initiation :
12/01/2015
Primary completion :
01/01/2022
Completion :
12/01/2022
HER-2 • ALK • ER • PGR • MSI
|
MSI-H/dMMR • ER negative • PGR negative
|
Opdivo (nivolumab) • eganelisib (IPI-549) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 3
Children's Oncology Group
Active, not recruiting
Last update posted :
03/25/2022
Initiation :
09/18/2006
Primary completion :
12/31/2015
TP53
|
TP53 mutation
|
cisplatin • doxorubicin hydrochloride • etoposide IV • Lysodren (mitotane) • Neupogen (filgrastim)
Phase 2
Canadian Cancer Trials Group
Active, not recruiting
Last update posted :
03/21/2022
Initiation :
07/14/2011
Primary completion :
07/06/2015
Completion :
09/30/2022
PTEN • STK11 • NF1
|
EGFR mutation • PTEN mutation • NF1 mutation • MTOR mutation • AKT1 amplification
|
Sutent (sunitinib) • Torisel (temsirolimus)
Phase 2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
03/14/2022
Initiation :
02/01/2016
Primary completion :
01/11/2019
Completion :
02/01/2023
PD-L1
|
Keytruda (pembrolizumab) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1
Y-mAbs Therapeutics
Active, not recruiting
Last update posted :
02/08/2022
Initiation :
04/01/2010
Primary completion :
04/01/2020
Completion :
09/01/2022
CD34
|
Omblastys (omburtamab I-131)
Phase 1/2
Enterome
Recruiting
Last update posted :
12/08/2021
Initiation :
07/23/2020
Primary completion :
05/30/2023
Completion :
03/30/2024
IFNG
|
Opdivo (nivolumab) • EO2401 • Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 1/2
National Eye Institute (NEI)
Completed
Last update posted :
11/01/2021
Initiation :
01/23/2017
Primary completion :
07/09/2019
Completion :
07/09/2019
VHL
|
VHL mutation
|
Fovista (pegpleranib) • Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • Lucentis (ranibizumab)
Phase N/A
St. Jude Children's Research Hospital
Recruiting
Last update posted :
08/24/2021
Initiation :
10/01/2001
Primary completion :
12/01/2040
Completion :
12/01/2040
TP53
|
TP53 mutation
Phase 3
Cortendo AB
Completed
Last update posted :
03/16/2021
Initiation :
09/26/2017
Primary completion :
06/30/2020
Completion :
08/31/2020
CRP
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • Recorlev (levoketoconazole)
Phase 2
M.D. Anderson Cancer Center
Recruiting
Last update posted :
01/25/2021
Initiation :
02/26/2018
Primary completion :
02/28/2021
Completion :
02/28/2021
ALB
|
Cabometyx (cabozantinib tablet)
Phase N/A
Haukeland University Hospital
Active, not recruiting
Last update posted :
08/04/2020
Initiation :
10/01/2016
Primary completion :
09/01/2020
Completion :
09/01/2020
CYP1A2
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection) • lignocaine
Phase 2
Dana-Farber Cancer Institute
Recruiting
Last update posted :
04/08/2020
Initiation :
12/28/2017
Primary completion :
05/31/2021
Completion :
05/31/2025
ALB
|
Opdivo (nivolumab) • Yervoy (ipilimumab)
Phase 2
Wake Forest University Health Sciences
Completed
Last update posted :
11/28/2019
Initiation :
08/01/2010
Primary completion :
06/27/2016
Completion :
06/27/2016
ALB
Phase N/A
Bnai Zion Medical Center
Unknown status
Last update posted :
01/18/2019
Initiation :
08/18/2016
Primary completion :
07/01/2018
Completion :
12/01/2019
TP53 • NRP1 • MCM2 • MCM3
|
TP53 expression
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase N/A
Fondazione Policlinico Universitario Agostino G...
Unknown status
Last update posted :
11/08/2017
Initiation :
03/17/2017
Primary completion :
11/17/2018
Completion :
03/17/2019
CRP
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase N/A
Centre Hospitalier Universitaire Dijon
Unknown status
Last update posted :
08/25/2017
Initiation :
01/01/2012
Primary completion :
01/01/2020
Completion :
12/01/2020
MEN1
|
Invega Sustenna (paliperidone palmitate extended-release 1-month injection)
Phase 2
National Cancer Institute (NCI)
Completed
Last update posted :
03/30/2015
Initiation :
01/01/2009
Primary completion :
04/01/2013
Completion :
10/01/2013
ALB
|
cixutumumab (IMC A12)
Phase 1
Children's Oncology Group
Completed
Last update posted :
01/30/2014
Initiation :
09/01/2009
Primary completion :
06/01/2013
ALB
|
SVV-001
Phase 2
Sidnei Epelman
Unknown status
Last update posted :
03/26/2013
Initiation :
03/01/2011
Primary completion :
06/01/2013
Completion :
12/01/2013
ERCC1
|
ERCC1 expression
|
oxaliplatin
Phase 1
National Cancer Institute (NCI)
Completed
Last update posted :
02/28/2013
Initiation :
08/01/1999
Primary completion :
02/01/2009
HER-2
|
HER-2 overexpression
|
Herceptin (trastuzumab) • carboplatin • albumin-bound paclitaxel